Welcome to our dedicated page for EyePoint SEC filings (Ticker: EYPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on EyePoint's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into EyePoint's regulatory disclosures and financial reporting.
EyePoint, Inc. reported an insider-related purchase involving a family trust associated with President and CEO Jay S. Duker. The trust bought 1,500 shares of common stock in an open-market transaction at $13.1492 per share.
After this trade, the family trust holds 100,665 shares of EyePoint common stock, while Duker directly owns 77,752 shares. The shares in the trust are for the benefit of his children, with his spouse serving as trustee, and Duker disclaims beneficial ownership of those trust-held shares.
EyePoint, Inc. Chief Financial Officer George Elston reported non-sale insider transactions involving company common stock. On March 2, 2026, he made bona fide gift transfers totaling 10,000 shares, with 5,000 shares from his directly held stock and 5,000 shares from stock reported as indirectly held.
Footnotes explain that some shares were transferred to an irrevocable family trust for the benefit of his immediate family, with JP Morgan Trust Company of Delaware as trustee. The filing states that he disclaims beneficial ownership of the securities held in the family trust.
EyePoint, Inc. is a clinical-stage biopharmaceutical company focused on serious retinal diseases using its Durasert E™ sustained drug delivery technology. Its lead candidate, DURAVYU™ (vorolanib in Durasert E), is in global Phase 3 trials for wet age-related macular degeneration and diabetic macular edema.
The company reports cash, cash equivalents and marketable securities of $306.1 million as of December 31, 2025, which it believes will fund operations into the fourth quarter of 2027, beyond expected Phase 3 wet AMD topline data in 2026. DURAVYU has shown favorable safety and efficacy in Phase 1 and 2 trials and is licensed regionally through Equinox/Betta.
EyePoint highlights extensive risk factors, including reliance on DURAVYU’s clinical and commercial success, the need for additional capital, an ongoing DOJ investigation related to historical DEXYCU® practices, and an FDA warning letter regarding YUTIQ® manufacturing that it states has been addressed with corrective actions. The company operates manufacturing facilities in Watertown and Northbridge, Massachusetts and employed 214 people as of February 27, 2026.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported insider transactions involving stock options and common shares. On March 4, 2026, he exercised a stock option covering 2,438 shares of common stock at an exercise price of $8.2600 per share and reported acquiring the corresponding common shares. He then sold 2,438 shares of common stock in open-market transactions at a weighted average price of $17.8719 per share, with individual sale prices ranging from $17.22 to $18.45. A separate option grant is disclosed as vesting 25% on January 3, 2026, with the remainder vesting monthly over the following three years.
EyePoint, Inc. reported weaker fourth-quarter and full-year 2025 results as it increased investment in its lead retinal drug candidate, DURAVYU. For 2025, total net revenue was $31.4 million versus $43.3 million in 2024, while operating expenses rose to $274.8 million from $189.1 million, driven mainly by Phase 3 trials in wet age-related macular degeneration (AMD) and diabetic macular edema (DME).
The company’s 2025 net loss widened to $232.0 million, or $3.17 per share, compared with a $130.9 million loss, or $2.32 per share, in 2024. Cash, cash equivalents and marketable securities totaled $306 million as of December 31, 2025, and EyePoint expects this to fund operations into the fourth quarter of 2027, through key Phase 3 milestones for DURAVYU.
Both pivotal Phase 3 DURAVYU trials in wet AMD (LUGANO and LUCIA, enrolling over 900 patients) remain on track for topline data beginning in mid-2026, with a data safety committee recommending continuation without changes. Phase 3 COMO and CAPRI trials in DME have begun dosing patients, with topline data expected in the second half of 2027, underscoring management’s focus on regulatory and commercial readiness for potential future launch.
EyePoint, Inc. reported that the first patients have been dosed in COMO and CAPRI, its two global Phase 3 trials of DURAVYU for diabetic macular edema. These randomized, aflibercept-controlled studies each plan to enroll about 240 patients and use a six‑month redosing schedule.
DURAVYU is an investigational sustained-release tyrosine kinase inhibitor designed to target both VEGF-driven vascular leakage and IL‑6–mediated inflammation. EyePoint also highlighted fully enrolled Phase 3 wet AMD trials with topline data expected in mid‑2026 and DME Phase 3 topline results anticipated in the second half of 2027.
The company’s March 2026 investor presentation notes approximately $300M in cash and investments, which it expects to fund operations into the fourth quarter of 2027, and describes commercial manufacturing scale-up in Massachusetts to support a potential DURAVYU launch.
EyePoint, Inc. Schedule 13G discloses that Paradigm-related reporting persons hold disclosed stakes in EyePoint's common stock as of the close of business on 02/17/2026.
The filing shows Paradigm BioCapital Advisors (and related entities) with 4,192,261 shares ( 5.1%) and Paradigm BioCapital International Fund Ltd. with 3,694,542 shares ( 4.5%). The ownership percentages are calculated using 82,787,220 shares outstanding as of 10/30/2025.
EyePoint, Inc. Chief Medical Officer Ramiro Ribeiro reported a set of option-related transactions. On February 17, 2026, he exercised stock options and acquired 2,437 shares of common stock at $8.26 per share, then sold 2,437 shares in an open-market transaction at $15.00 per share. Following these moves, he reported holding 85,313 stock options and no directly held common shares from this transaction. A disclosed option award vests 25% on January 3, 2026, with the remainder vesting monthly over the next three years.
Eyepoint, Inc. received an amended Schedule 13G from TCG Crossover Fund II, TCG Crossover GP II and Chen Yu reporting beneficial ownership of 3,572,335 shares of common stock, representing 4.3% of the class based on 82,787,220 shares outstanding as of October 30, 2025.
The reporting persons indicate they share voting and dispositive power over these shares through the fund structure and related entities, while disclaiming group status and beneficial ownership beyond their pecuniary interest. They also certify the holdings are passive and not intended to change or influence control of Eyepoint.